Takayasu's arteritis (patient information): Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 5: Line 5:
'''Editor-in-Chief:''' Alexandra M. Palmer
'''Editor-in-Chief:''' Alexandra M. Palmer


{{EJ}}
 


==What is Takayasu's  arteritis?==
==What is Takayasu's  arteritis?==
Line 29: Line 29:
{{Reflist}}
{{Reflist}}


{{SIB}}
 
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Patient information]]
[[Category:Patient information]]

Revision as of 16:40, 20 August 2012

For the WikiDoc page for this topic, click here

WikiDoc Resources for Takayasu's arteritis (patient information)

Articles

Most recent articles on Takayasu's arteritis (patient information)

Most cited articles on Takayasu's arteritis (patient information)

Review articles on Takayasu's arteritis (patient information)

Articles on Takayasu's arteritis (patient information) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Takayasu's arteritis (patient information)

Images of Takayasu's arteritis (patient information)

Photos of Takayasu's arteritis (patient information)

Podcasts & MP3s on Takayasu's arteritis (patient information)

Videos on Takayasu's arteritis (patient information)

Evidence Based Medicine

Cochrane Collaboration on Takayasu's arteritis (patient information)

Bandolier on Takayasu's arteritis (patient information)

TRIP on Takayasu's arteritis (patient information)

Clinical Trials

Ongoing Trials on Takayasu's arteritis (patient information) at Clinical Trials.gov

Trial results on Takayasu's arteritis (patient information)

Clinical Trials on Takayasu's arteritis (patient information) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Takayasu's arteritis (patient information)

NICE Guidance on Takayasu's arteritis (patient information)

NHS PRODIGY Guidance

FDA on Takayasu's arteritis (patient information)

CDC on Takayasu's arteritis (patient information)

Books

Books on Takayasu's arteritis (patient information)

News

Takayasu's arteritis (patient information) in the news

Be alerted to news on Takayasu's arteritis (patient information)

News trends on Takayasu's arteritis (patient information)

Commentary

Blogs on Takayasu's arteritis (patient information)

Definitions

Definitions of Takayasu's arteritis (patient information)

Patient Resources / Community

Patient resources on Takayasu's arteritis (patient information)

Discussion groups on Takayasu's arteritis (patient information)

Patient Handouts on Takayasu's arteritis (patient information)

Directions to Hospitals Treating Takayasu's arteritis (patient information)

Risk calculators and risk factors for Takayasu's arteritis (patient information)

Healthcare Provider Resources

Symptoms of Takayasu's arteritis (patient information)

Causes & Risk Factors for Takayasu's arteritis (patient information)

Diagnostic studies for Takayasu's arteritis (patient information)

Treatment of Takayasu's arteritis (patient information)

Continuing Medical Education (CME)

CME Programs on Takayasu's arteritis (patient information)

International

Takayasu's arteritis (patient information) en Espanol

Takayasu's arteritis (patient information) en Francais

Business

Takayasu's arteritis (patient information) in the Marketplace

Patents on Takayasu's arteritis (patient information)

Experimental / Informatics

List of terms related to Takayasu's arteritis (patient information)

Editor-in-Chief: Alexandra M. Palmer


What is Takayasu's arteritis?

Takayasu's arteritis is an inflammatory disease of unknown etiology that affects the aorta and its branches. Although it has been reported worldwide, it shows a predilection for young Asian women. Females with this disease outnumber males by 8:1, and the age of onset is typically between 15 and 30 years. In the Western world, atherosclerosis is a more frequent cause of obstruction of the aortic arch vessels than is Takayasu's arteritis.

What are the symptoms of Takayasu's arteritis?

About half of all patients develop an initial systemic illness with symptoms of malaise, fever, night sweats, weight loss, arthralgia, and fatigue. There is often an anemia and marked elevation of the ESR. This phase gradually subsides and is followed by a more chronic stage characterized by inflammatory and obliterative changes in the aorta and its branches. The other half of patients with Takayasu's arteritis present with only late vascular changes, without an antecedent systemic illness. In the late stage, weakness of the arterial walls may give rise to localized aneurysms.

Four types of late-phase Takayasu arteritis are described on the basis of the sites of involvement as follows:[1]

  • Type I - Classic pulseless type that involves the brachiocephalic trunk, carotid arteries, and subclavian arteries
  • Type II - Combination of type I and III
  • Type III - Atypical coarctation type that involves the thoracic and abdominal aortas distal to the arch and its major branches
  • Type IV - Dilated type that involves extensive dilatation of the length of the aorta and its major branches

Treatment

The great majority of patients with Takayasu’s arteritis respond to prednisone. The usual starting dose is approximately 1 milligram per kilogram of body weight per day (for most people, this is approximately 60 milligrams a day). Because of the significant side effects of long-term high–dose prednisone use, the starting dose is tapered over several weeks to a dose that the physician feels is tolerable for the patient.

Where to find medical care for Takayasu's arteritis

Directions to Hospitals Treating Takayasu's arteritis

Sources

  1. "eMedicine - Arteritis, Takayasu : Article by Robert L Cirillo, Jr, MD, MBA". Retrieved 2007-07-19.


Template:WH Template:WS